Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction

Zile, Michael R.; Lindenfeld, JoAnn; Weaver, Fred A.; Zannad, Faı̈ez; Galle, Elizabeth; Rogers, Tyson; Abraham, William T.

doi:10.1016/j.jacc.2020.05.015

Cited by 123 publications

(128 citation statements)

References 23 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…U istraživanju BeAT-HF BAT je bila sigurna terapija i znatno je poboljšala učestalost simptoma, kvalitetu života, podnošenje napora, kao i vrijednost NT-proBNP. 142 Na temelju navedenih podataka, BAT je odobren u SAD-u, dok će praćenje rezultata BeAT-HF studije pokazati učinak na značajne ishode.…”

Section: Srčana Resinkronizacijska Terapija (Studija Stop-crt)unclassified

See 1 more Smart Citation

The year in cardiovascular medicine 2020: heart failure and cardiomyopathies

Bueno

Moura

Lancellotti

et al. 2021

European Heart Journal

View full text Add to dashboard Cite

show abstract

Section: Srčana Resinkronizacijska Terapija (Studija Stop-crt)unclassified

“…In the BeAT-HF study, BAT was safe and significantly improved symptoms, quality of life, exercise capacity, and NT-proBNP. 142 On the basis of these data, BAT was approved in the USA, while ongoing follow-up in the BeAT-HF study will assess effects on hard outcomes.…”

Section: Specifična Liječenja Telemedicina I Druge Vrste Praćenja Na Daljinumentioning

confidence: 99%

The year in cardiovascular medicine 2020: heart failure and cardiomyopathies

Bueno

Moura

Lancellotti

et al. 2021

European Heart Journal

View full text Add to dashboard Cite

show abstract

“…However, it is not impossible that microcurrent may have had a beneficial effect on cardiac function and in turn on exercise capacity, NYHA classification, and quality of life of patients. 11,13,14,[24][25][26][27][28] In particular, the rapid improvement is an observation that requires further reflections.…”

Section: Discussionmentioning

confidence: 99%

Cardio‐microcurrent device for chronic heart failure: first‐in‐human clinical study

et al. 2021

View full text Add to dashboard Cite

Aims Most devices for treating ambulatory Class II and III heart failure are linked to electrical pulses. However, a steady electric potential gradient is also necessary for appropriate myocardial performance and may be disturbed by structural heart diseases. We investigated whether chronic application of electrical microcurrent to the heart is feasible and safe and improves cardiac performance. The results of this study should provide guidance for the design of a two-arm, randomized, controlled Phase II trial. Methods and results This single-arm, non-randomized pilot study involved 10 patients (9 men; mean age, 62 ± 12 years) at two sites with 6 month follow-up. All patients had New York Heart Association (NYHA) Class III heart failure and non-ischaemic dilated cardiomyopathy, with left ventricular ejection fraction (LVEF) <35%. A device was surgically placed to deliver a constant microcurrent to the heart. The following tests were performed at baseline, at hospital discharge, and at six time points during follow-up: determination of LVEF and left ventricular end-diastolic/end-systolic diameter by echocardiography; the 6 min walk test; and assessment of NYHA classification and quality of life (36-Item Short-Form Health Survey questionnaire). Microcurrent application was feasible and safe; no device-related or treatment-related adverse events occurred. During follow-up, rapid and significant signal of efficacy (P < 0.005) was present with improvements in LVEF, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, and distance walked. For eight patients, NYHA classification improved from Class III to Class I (for seven, as early as 14 days post-operatively); for one, to Class II; and for one, to Class II/III. 36-Item Short-Form Health Survey questionnaire scores also improved highly significantly. Conclusions Chronic application of microcurrent to the heart is feasible and safe and leads to a rapid and lasting improvement in heart function and a near normalization of heart size within days. The NYHA classification and quality of life improve just as rapidly.

show abstract

“…In the recently published BEAT-HF study, Baroreceptor Activation Therapy (BAT) benefited patients with EF ≤ 35% and NT-proBNP ≤1600 who were not indicated for CRT [23]. While the initial data appear to be promising, additional studies validating these results are needed.…”

Section: Alternative Devicesmentioning

confidence: 99%

Cardiac contractility modulation for the treatment of moderate to severe HF

Rao

Burkhoff

2020

Expert Review of Medical Devices

View full text Add to dashboard Cite

Introduction: Heart failure (HF) affects over 6 million Americans and approximately 650,000 new cases are diagnosed annually, with patients evenly split between HFrEF and HFpEF. Recent advances in therapy for these patients have been limited to pharmaceutical agents, with CRT remaining the most reliable device therapy option since its advent almost twenty years ago. In 2019, after almost two decades without the introduction of a new device therapy for the treatment of moderate HF, the FDA approved CCM ® therapy, delivered by the Optimizer Smart device, for patients with NYHA Class III HF who are on guideline-directed medical therapy (GDMT), in normal sinus rhythm (NSR), and with EF ranging from 25% to 45%, and who are ineligible for CRT. Areas covered: Multiple clinical trials support the use of CCM to improve quality of life, functional class, and 6-min hall walk distance. This article will discuss the science behind CCM therapy, the presumed mechanisms of action, the pre-clinical studies that shaped subsequent endeavors, and the clinical trials that support its use. Expert opinion: The introduction of CCM therapy bridges a therapeutic gap for patients with few or no other therapeutic options for NYHA III heart failure.

show abstract

Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction

Cited by 123 publications

References 23 publications

The year in cardiovascular medicine 2020: heart failure and cardiomyopathies

The year in cardiovascular medicine 2020: heart failure and cardiomyopathies

Cardio‐microcurrent device for chronic heart failure: first‐in‐human clinical study

Cardiac contractility modulation for the treatment of moderate to severe HF

Contact Info

Product

Resources

About